Stopping GLP-1 drugs can quickly erase cardiovascular benefits – BioNews Central Stopping or interrupting GLP-1 drugs for six months or more in type 2 diabetes patients raises the risk of major cardiovascular events by up to 22%, undoing previous benefits. ...

Stopping or interrupting #GLP1Drugs for six months or more in #Type2Diabetes patients raises the risk of major #CardiovascularEvents by up to 22%, undoing previous benefits. 
#GLP1 #GLP1Medications #CardiovascularRisk

GPs warn against rushed PBS subsidy for weight-loss drugs amid doctor concerns Novo Nordisk pushes for Ozempic PBS expansion to adolescents, but medical leaders cite evidence gaps and budget concerns. One in four Australian children have obesity.

GPs warn against rushed PBS subsidy for weight-loss drugs amid doctor concerns

#GLP1Drugs #ChildObesity #AusHealthPolicy #AusNews

thedailyperspective.org/article/2026-03-16-gps-w...

Stopping GLP-1 weight loss drugs linked to weight regain and reversal of heart health markers – BioNews Central Stopping GLP-1 weight loss drugs is followed by weight regain and a reversal of the beneficial effects on heart and metabolic health markers. ...

Stopping #GLP1 #WeightLossDrugs is followed by #WeightRegain and a reversal of the beneficial effects on #heart and #MetabolicHealth markers.
#GLP1Drugs #HeartHealth

WHO Backs GLP-1 Drugs for Treating Obesity: A Turning Point in the Global Fight Against a Growing Health Crisis - The WHO’s endorsement of GLP-1 drugs marks a turning point in the global response to obesity. For millions, these medicines

WHO Backs GLP-1 Drugs for Treating Obesity: A Turning Point in the Global Fight Against a Growing Health Crisis wiobs.com/who-backs-gl... #WHO #ObesityCrisis #GLP1Drugs #GlobalHealth #PublicHealth

Suicidal Thoughts Prompt New Warnings From Health Authorities For GLP-1 Drugs Talk to your doctor.

Suicidal Thoughts Prompt New Warnings From Health Authorities For GLP-1 Drugs #Science #HealthandMedicine #MentalHealth #GLP1Drugs #MentalHealthAwareness #SuicidalThoughts

There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet...

There may not be a safe off-ramp for some taking GLP-1 drugs, study suggests #Technology #Other #GLP1drugs #HealthStudy #Pharmaceuticals

Novo, Lilly sign MFN pricing deal with Trump administration The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

#NovoNordisk #Lilly #EliLilly #MFN #MostFavouredNation #MFNpricingdeal #Trump #pricingagreement #GLP1drugs #FDA #patientaccess #pharmaceuticalpricing #medicineprices #semaglutide #Ozempic #diabetes #Wegovy #obesity #TrumpRx #Zepbound #Mounjaro
pharmaphorum.com/news/novo-li...

GLP-1 Drugs Like Ozempic Work, but New Research Reveals a Major Catch Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded studies raise concerns. Three new reviews from Cochrane have found that GLP-1...

GLP-1 Drugs Like Ozempic Work, but New Research Reveals a Major Catch #Science #HealthandMedicine #Pharmacology #GLP1drugs #Ozempic #HealthResearch

US Obesity Rates Have Dropped, And GLP-1 Drugs May Explain Why Could this be a turning point?

US Obesity Rates Have Dropped, And GLP-1 Drugs May Explain Why #Science #HealthandMedicine #PublicHealth #ObesityResearch #GLP1Drugs

Study Finds Weight-Loss Surgery Outperforms GLP-1 Drugs for Long-Term Health Surgery reduces the risks of death, heart disease, kidney failure, and eye damage more effectively than GLP-1 medicines. A major study conducted at Cleveland Clinic found that individuals with obesity...

Study Finds Weight-Loss Surgery Outperforms GLP-1 Drugs for Long-Term Health #Science #HealthandMedicine #WeightManagement #WeightLossSurgery #GLP1Drugs #HealthOutcomes

A new study finds children and teens with obesity or diabetes who take GLP-1 weight-loss medications experience significant improvements in many cardiometabolic risk factors, but long-term safety questions remain.

youtu.be/YVMGmi4CfXs

#GLP1 #ChildHealth #TeenHealth #PediatricObesity #GLP1Drugs

One in four US adults with diabetes used a GLP-1 drug last year, survey finds By Bhanvi Satija (Reuters) -More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United States for treating type 2 diabetes. They are sold as Zepbound and Wegovy, respectively, for weight loss and are being tested for other conditions. Use of the injectable drugs was highest among adults with diabetes aged 50–64 at 33.3%, reflecting the more significant disease burden in this group, the report said. A quarter or 25.3% of adults with diabetes aged 18 to 34 reported using a GLP-1 drug, while the adoption rate was 20.8% among those 65 and older. The data are from a nationally representative annual survey of U.S. adults aged 18 and older that was conducted in person and with follow-up by phone in 2024. In 2024, for the first time, participants in the annual survey who had diabetes were asked if they were using the Lilly or Novo blockbusters or other GLP-1 drugs to lower blood sugar or lose weight. The drugs mimic the activity of a hormone that regulates blood sugar levels, slows digestion and helps people feel full for longer. Drugmakers Lilly and Novo have faced criticism about the cost of the treatments, which carry a list price of about $1,000 for a month’s supply. Roughly 31% of survey participants who reported using insulin also reported using GLP-1 drugs, as did about 28% of patients who were using oral drugs to control their blood sugar, according to the report, indicating that these treatments are being integrated into combination regimens. Only 12.1% of Asian non-Hispanic adults with diabetes used the drugs, which may reflect disparities in access or adoption of the therapies. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if LLY is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #DiabetesAwareness #GLP1Drugs #Type2Diabetes #HealthCare #Mounjaro

Experts Recommend Healthy Lifestyle Changes Alongside GLP-1 Drug Use - Drugs.com MedNews WEDNESDAY, July 16, 2025 GLP-1 weight-loss drugs like Ozempic and Zepbound are so effective it might seem that a person can lose weight without doing anything a

New JAMA research: GLP-1 drugs like Ozempic need lifestyle changes to work safely. People lose 25-40% weight as muscle mass. Solution: prioritize protein (20-30g per meal), strength training, and manage GI side effects properly. #GLP1Drugs www.drugs.com/news/experts...

UK probes link between GLP-1 drugs and pancreatitis The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

#GLP1drugs #pancreatitis #MHRA #GLP1receptoragonists #weightloss #type2diabetes #GLP1sideeffects #MHRA #GenomicsEngland #NovoNordisk #Ozempic #Wegovy #semaglutide #EliLilly #Mounjaro #tirzepatide #chronicpancreatitis #YellowCardBiobankproject
pharmaphorum.com/news/uk-prob...

Real-World Results For GLP-1 Drugs Underwhelm, Study Says - Drugs.com MedNews WEDNESDAY, June 11, 2025 Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren t as impressive as those promised by the dru

Real-world GLP-1 weight loss study: Patients lost 9% body weight vs 15-21% in clinical trials. Ozempic, Wegovy, and Zepbound underperform in practice due to higher quit rates, lower dosing. Published in the Obesity journal. #GLP1Drugs www.drugs.com/news/real-wo...

If These Drugs Had Existed, My Life Would’ve Been Different GLP-1s didn’t just shrink me. They saved me.

These drugs didn’t make me perfect.
They made me possible.
medium.com/illumination...
#OzempicJourney #GLP1Drugs #HealthNarratives #Zepbound #TransformationStory

Vision loss: GLP-1 drugs like Ozempic linked to 3 eye conditions A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

🔬 🔬 GLP-1 drugs like Ozempic linked to 3 eye conditions

#Visionloss #Glp1drugs

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

💉 💉 GLP-1 drugs could lower risk of lung issues

#Diabetesandcopd #Glp1drugs

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesAndCOPD #GLP1Drugs #LungHealth

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesAndCOPD #GLP1Drugs #COPDRiskReduction

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesCOPD #GLP1Drugs #COPDPrevention

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesAndCOPD #GLP1Drugs #COPDLungHealth

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesAndCOPD #GLP1Drugs #COPDSymptomFlareUps

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesCOPD #GLP1Drugs #COPDPrevention

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesAndCOPD #GLP1Drugs #LowerRiskOfCOPD

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesCOPD #DiabetesRisks #GLP1Drugs

Diabetes and COPD: GLP-1 drugs could lower risk of lung issues People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those other diabetes drugs.

www.medicalnewstoday.com/articles/can-drugs-like-...

#DiabetesCOPD #GLP1Drugs #SGLT2Medications

Kalundborg, Denmark Expansion of production facilities to be completed 2029. Image provided by Novo Nordisk.

Novo Nordisk and Eli Lilly have significantly expanded their GLP-1 drug manufacturing capacities, resolving supply issues and removing most products from the FDA's shortage list.

jcst2d.com/index.php?vi...

#PharmaceuticalManufacturing #GLP1Drugs #NovoNordisk #EliLilly #FDAUpdates

Big Food profits off addiction, then pharma profits off GLP-1s to 'fix' it. The real fix? Ending the corporate stranglehold on our plates. #GLP1Drugs #FoodSystemReform #HealthRevolution